Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DHM3X5
|
|||
| Drug Name |
NFX-179
|
|||
| Synonyms |
Nedometinib; NFX-179; K5T4I78IYZ; 2252314-46-6; 2-[(2-fluoro-4-iodophenyl)amino]-N-(2-hydroxyethoxy)-1-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide; 2-((2-Fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)-1-methyl-1H-pyrrolo(2,3-b)pyridine-3-carboxamide; UNII-K5T4I78IYZ; NFX179; SCHEMBL21979494; GTPL12872; Example 2 [US11161845B2]; HY-156625; CS-0886460; EN300-27122249; 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1-methylpyrrolo[2,3-b]pyridine-3-carboxamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Neurofibromatosis 1 [ICD-11: LD2D.10] | Phase 2 | [1] | |
| Company |
NFlection Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H16FIN4O3
|
|||
| Canonical SMILES |
CN1C2=C(C=CC=N2)C(=C1NC3=C(C=C(C=C3)I)F)C(=O)NOCCO
|
|||
| InChI |
InChI=1S/C17H16FIN4O3/c1-23-15-11(3-2-6-20-15)14(17(25)22-26-8-7-24)16(23)21-13-5-4-10(19)9-12(13)18/h2-6,9,21,24H,7-8H2,1H3,(H,22,25)
|
|||
| InChIKey |
SENAOZROGSYRTD-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | ERK activator kinase (MEK) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04435665) A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2a Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of NFX-179 Gel in Subjects With Cutaneous Neurofibromas. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of NFlection Therapeutics | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.